NEJM Zepbound FDA Prescribing Information, section 6.1, NDA 217806, Eli Lilly, 2024
We do not yet have clear answers on: Long-term safety Optimal dosing strategies Metabolic interactions Effects on weight loss outcomes Some patients who stop GLP-1 treatment may see lost weight return over time
You can have 30-day or 90-day check-in cadences, async portal check-ins, or live video/phone visits
While NAION is rare, the rates among Rybelsus patients were high enough to catch the attention of the medical community and prompt recent changes to the Rybelsus label in Europe
As weight management is critical in diabetes care, this benefit aligns with our holistic approach to improving insulin sensitivity and overall health outcomes
Mounjaro and Zepbound are both injections that contain tirzepatide (the active ingredient)